Clinical Research Of TACE Combined With HIFU In Treating Elderly Patients With Primary Liver Cancer

Objective To evaluate clinical therapeutic efficacy of Transarterial chemotherapy embolization(TACE) combined with High intensity focused ultrasound(HIFU) compared with single TACE in treating elderly patients(≧60 years old) with primary liver cancer.Methods Clinical datas of 72 elderly patients with primary liver cancer in our hospital were retrospectively analyzed. They were divided into TACE combined with HIFU group(combination group: n=36) and TACE group(TACE group: n=36) according to the treatment. Compared tumor shrunk, the change of AFP, AST, ALT value, median survival time, 1-year, 2-years, 3-year survival rates in two groups.Results The degree of tumor shrunk in combination group were greater than that of TACE group(P < 0.05), meanwhile, AFP value decreased more in combination group(P<0.05); median survival time, 1-year, 2-years, 3-year survival rates were(32.0 ± 6.9) months, 83.1%, 57.3%, 42.6% and(21.0 ± 6.3) months, 62.9%, 41.4%, 22.3% respectively, The difference had statistical significance(P<0.05). there were on severe complications in both groups.Conclusion The treatment of TACE combined with HIFU is effective and safe in treating elderly patients with primary liver cancer and can make more clinical benefits compared with single TACE.